Back to Search Start Over

Prostaglandin E2-Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti-PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection.

Authors :
Yamato Sajiki
Satoru Konnai
Tomohiro Okagawa
Asami Nishimori
Naoya Maekawa
Shinya Goto
Kei Watari
Minato, Erina
Atsushi Kobayashi
Junko Kohara
Shinji Yamada
Mika K. Kaneko
Yukinari Kato
Hirofumi Takahashi
Nobuhiro Terasaki
Akira Takeda
Keiichi Yamamoto
Mikihiro Toda
Yasuhiko Suzuki
Shiro Murata
Source :
Journal of Immunology. 9/1/2019, Vol. 203 Issue 5, p1313-1324. 12p.
Publication Year :
2019

Abstract

Bovine leukemia virus (BLV) infection is a chronic viral infection of cattle and endemic in many countries, including Japan. Our previous study demonstrated that PGE2, a product of cyclooxygenase (COX) 2, suppresses Th1 responses in cattle and contributes to the progression of Johne disease, a chronic bacterial infection in cattle. However, little information is available on the association of PGE2 with chronic viral infection. Thus, we analyzed the changes in plasma PGE2 concentration during BLV infection and its effects on proviral load, viral gene transcription, Th1 responses, and disease progression. Both COX2 expression by PBMCs and plasma PGE2 concentration were higher in the infected cattle compared with uninfected cattle, and plasma PGE2 concentration was positively correlated with the proviral load. BLV Ag exposure also directly enhanced PGE2 production by PBMCs. Transcription of BLV genes was activated via PGE2 receptors EP2 and EP4, further suggesting that PGE2 contributes to disease progression. In contrast, inhibition of PGE2 production using a COX-2 inhibitor activated BLV-specific Th1 responses in vitro, as evidenced by enhanced T cell proliferation and Th1 cytokine production, and reduced BLV proviral load in vivo. Combined treatment with the COX-2 inhibitor meloxicam and anti-programmed death-ligand 1 Ab significantly reduced the BLV proviral load, suggesting a potential as a novel control method against BLV infection. Further studies using a larger number of animals are required to support the efficacy of this treatment for clinical application. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00221767
Volume :
203
Issue :
5
Database :
Academic Search Index
Journal :
Journal of Immunology
Publication Type :
Academic Journal
Accession number :
138293704
Full Text :
https://doi.org/10.4049/jimmunol.1900342